Last reviewed · How we verify
RSV Vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus (RSV) proteins, preventing or reducing severity of RSV infection.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus (RSV) proteins, preventing or reducing severity of RSV infection. Used for Prevention of RSV disease in adults aged 60 years and older.
At a glance
| Generic name | RSV Vaccine |
|---|---|
| Also known as | Respiratory syncytial virus, ABRYSVO, RSVpreF |
| Sponsor | Pfizer |
| Drug class | Recombinant protein subunit vaccine |
| Target | Respiratory syncytial virus (RSV) fusion (F) glycoprotein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Pfizer's RSV vaccine (Arexvy) is a recombinant glycoprotein F (RSV F) subunit vaccine that presents the RSV fusion protein to the immune system, triggering both humoral and cell-mediated immune responses. This approach avoids the risk of disease enhancement seen with older inactivated RSV vaccines, providing protective immunity against RSV infection and disease.
Approved indications
- Prevention of RSV disease in adults aged 60 years and older
Common side effects
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Injection site erythema
- Fever
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women (PHASE1)
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose (PHASE3)
- A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control (PHASE3)
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate (PHASE1, PHASE2)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV Vaccine CI brief — competitive landscape report
- RSV Vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI